Chesley Taft & Associates LLC Q1 2023 vs. Q2 2023 13F Holdings Comparison
Ava Hoppe | 28 July, 2023
Microsoft, Apple, and Alphabet Among Top Holdings for Chesley Taft & Associates
Chesley Taft & Associates LLC, a prominent investment firm, recently disclosed its 13F holdings for Q1 2023 and Q2 2023. The report reveals the changes in the firm's portfolios, showcasing the gains and losses in various stocks. Among the top holdings are tech giants Microsoft, Apple, and Alphabet. While some holdings experienced notable increases in shares and value, others saw slight changes or even experienced a decrease. Let's delve deeper into the 13F holdings of Chesley Taft & Associates LLC.
Microsoft Corporation (MSFT) remains a strong contender in the portfolio, with 251,192 shares held in Q1 2023. Despite a slight decrease of 3,600 shares in Q2 2023, the value of the shares increased from $72,418,000 to $84,314,000. This translates to a 16.4% change, indicating consistent growth.
Another tech giant, Apple Inc (AAPL), holds a significant position in Chesley Taft & Associates' portfolio. The firm owned 360,493 shares in Q1 2023, which decreased by 5,685 shares in Q2 2023. However, the value of these shares rose from $59,445,000 to $68,822,000, demonstrating a 15.8% increase.
Alphabet Inc (GOOG), the parent company of Google, is also among the top holdings for Chesley Taft & Associates. With 472,396 shares held in Q1 2023, the firm experienced a slight decrease of 1,780 shares in Q2 2023. Nevertheless, the value of these shares rose from $49,129,000 to $56,930,000, signifying a 15.9% increase.
Moving beyond the tech sector, Chesley Taft & Associates also holds positions in other industries. For instance, PepsiCo Inc (PEP) saw a minimal decrease of 2,854 shares from Q1 2023 to Q2 2023. Despite this, the value of the shares remained stable, going from $45,000,000 to $45,192,000, resulting in a 0.4% change.
Stryker Corporation (SYK), a medical technology company, experienced a similar trend. Although there was a marginal decrease of 2,015 shares, the value of these shares saw a slight increase from $42,590,000 to $44,903,000, representing a 5.4% change.
Johnson & Johnson (JNJ), a renowned pharmaceutical and consumer goods company, saw a notable decrease in shares. Chesley Taft & Associates held 225,564 shares in Q1 2023, which decreased to 212,924 shares in Q2 2023. However, the value of these shares remained relatively stable at $34,962,000 and $35,243,000, resulting in a 0.8% change.
Costco Wholesale Corporation (COST) also holds a position in Chesley Taft & Associates' portfolio. Despite a minimal decrease of 50 shares, the value of these shares showed an increase from $32,536,000 to $35,227,000. This represents an 8.3% change, indicating positive growth.
Broadcom Inc (AVGO), a leading semiconductor company, experienced a substantial increase in shares held by Chesley Taft & Associates LLC. The firm owned 23,749 shares in Q1 2023, which increased to 37,466 shares in Q2 2023. The value of these shares also rose significantly from $15,235,000 to $32,499,000, resulting in a remarkable 113.3% change.
Amazon.com Inc (AMZN), a global e-commerce giant, witnessed minimal changes in the number of shares held. With only a difference of 565 shares between Q1 2023 and Q2 2023, the value of these shares increased from $23,887,000 to $30,074,000, representing a significant growth of 25.9%.
JPMorgan Chase & Co (JPM), one of the largest investment banks, experienced a slight decrease of 1,706 shares. Nonetheless, the value of these shares increased from $27,033,000 to $29,924,000, resulting in a 10.7% change.
Accenture PLC Ireland (ACN), a multinational professional services company, holds a stable position in the portfolio. While there was a marginal increase of 1,341 shares, the value of these shares experienced a 9.5% change, going from $27,223,000 to $29,806,000.
These are just a few examples from the extensive list of holdings disclosed by Chesley Taft & Associates LLC. The firm's portfolio showcases a diverse range of investments, from tech giants to pharmaceutical companies and beyond. As the year progresses, these holdings will continue to evolve, influenced by market trends, economic conditions, and the firm's investment strategies.
Disclaimer: The above article is for informational purposes only. It is not investment advice and should not be considered as a recommendation to buy or sell any securities. Investments are subject to market risks, and readers should consult with a financial advisor before making investment decisions.
Other Posts
- Simplifying Healthcare Administration: S&S Health Welcomes Don Weinstein and Richard Fleder to Board of Directors
- Towercrest Capital Management Q3 2022 vs. Q4 2022 13F Holdings Comparison
- Moon Capital Management LP's Q4 2022 Report: Notable Stock Changes and Investment Strategy
- Steinberg Asset Management LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison
- Trend Analysis: American Asset Management's Portfolio Evolution from Q4 2023 to Q1 2024
- Chatham Capital Group, Inc. Q3 2023 vs. Q4 2023 13F Holdings Comparison
- Patricia Melcher Joins NOV Inc. Board of Directors, Bringing Decades of Energy Investing Experience
- A Deep Dive into Cutter & CO Brokerage Q3/Q4 13F Holdings Comparison
- Excellence Imagerie: Revolutionizing French Radiology with Key Partner Antin and Radiologists
- Antin Infrastructure Partners: Transforming Infrastructure for a Sustainable Future